Abreva is a drug owned by Haleon Us Holdings Llc. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 28, 2014. Details of Abreva's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US4874794 | Inflammatory disease treatment |
Apr, 2014
(10 years ago) |
Expired
|
| US5534554 | Sucrose ester-C20 to C28 alcohol formulations |
Dec, 2013
(11 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Abreva is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Abreva's family patents as well as insights into ongoing legal events on those patents.
Abreva's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Abreva's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 28, 2014 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Abreva Generic API suppliers:
Docosanol is the generic name for the brand Abreva. 5 different companies have already filed for the generic of Abreva, with Alembic having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Abreva's generic
About Abreva
Abreva is a drug owned by Haleon Us Holdings Llc. It is used for treating cold sores and fever blisters on the face or lips by shortening healing time and reducing symptoms. Abreva uses Docosanol as an active ingredient. Abreva was launched by Haleon Us Holdings in 2000.
Approval Date:
Abreva was approved by FDA for market use on 25 July, 2000.
Active Ingredient:
Abreva uses Docosanol as the active ingredient. Check out other Drugs and Companies using Docosanol ingredient
Treatment:
Abreva is used for treating cold sores and fever blisters on the face or lips by shortening healing time and reducing symptoms.
Dosage:
Abreva is available in cream form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 10% | CREAM | Over the counter | TOPICAL |